NotablePrimary and study completion pushed from Aug 2027 to May 2028Show 4 more changesShow less
Enrollment increased: 121 → 142 participants
Trial sites reduced: 23 → 20 locations
Trial arms changed: 10 → 11
Eligibility criteria expanded, about 6 words
MinorTrial status changed: Recruiting → Active, Not Recruiting
Study sites revised (23)
v11
MinorEnrollment increased: 87 → 121 participants
Trial sites expanded: 2 → 23 locations
Primary and study completion moved earlier from Sep 2027 to Aug 2027
Trial arms changed: 6 → 10
v10
Minor7 versionsRe-verified since Feb 13, 2026, no change to tracked fieldsv3-v9
NotableTrial status: Not Yet Recruiting to Recruiting
Study sites: 0 to 2
Primary and study completion dates: Jul 2027 to Sep 2027
Start date changed from estimate of Dec 1, 2025 to Nov 24, 2025
v2
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess how safe, effective, and tolerable ABBV-547 is in adult participants in the United States and Japan.
There will be 2 parts to this study. In Part 1, participants are placed in one of 7 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 4 chance participants will receive placebo. In Part 2, participants are placed in one of 4 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 7 chance participants will receive placebo. Group 11 is the only group that will receive multiple doses. Approximately 142 adult participants will be enrolled at approximately 21 sites in the United States and Japan.
Participants will be administered one dose or multiple doses of ABBV-547 or placebo.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.